Rapid Micro Biosystems, Inc. posted strong FY25 revenue growth, driven by Growth Direct system placements, but remains unprofitable with a $47M net loss. RPID's growth hinges on large multi-system ...

The Company currently expects total revenue of between $6.2 million and $6.4 million in the fourth quarter of 2023, representing growth of approximately 45% compared to the prior-year period. The ...

Rapid Micro Biosystems and Merck KGaA have signed a five-year global distribution agreement for Growth Direct systems and consumables. Rapid Micro Biosystems, Inc. has entered a five-year global ...

Included a multi-system order at an additional site of an existing top 20 global pharma customer as part of their global Growth Direct system rollout Achieved inflection in gross margins to positive 8 ...

Robert Spignesi, CEO, opened by highlighting third quarter revenue of $7.8 million, which was above the midpoint of guidance and marked the twelfth consecutive quarter meeting or beating revenue ...

Rapid Micro Biosystems (NASDAQ:RPID) reported first-quarter 2026 revenue growth and reaffirmed its full-year outlook, citing momentum in system placements, consumables and recurring revenue, while ...

Rapid Micro Biosystems, Inc. reports earnings inline with expectations. Reported EPS is $-0.22 EPS, expectations were $-0.22. Operator: Thank you for standing by. My name is Eloisa, and I will be your ...

LEXINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company” or “Rapid Micro”), an innovative life sciences technology company providing mission ...

The new Rapid Sterility application includes a novel, proprietary test kit that has been developed for use with the Company’s fully automated Growth Direct system and delivers time to organism ...

Rapid Micro Biosystems, Inc. Class A ((RPID)) has held its Q1 earnings call. Read on for the main highlights of the call. Rapid Micro posted Q1 2026 revenue of $8.0 million, up 11% from $7.2 million a ...